Chemo plus radiation versus radiation alone for one plasmacytoma
Treatments studied
Part of Cancer clinical trials.
This Phase 2 study compares giving chemotherapy with radiation versus radiation alone for people with a single plasmacytoma (a localized plasma-cell tumor). It aims to see whether adding chemotherapy improves control of the disease while keeping side effects acceptable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solitary plasmacytoma (one localized tumor).
- You have not received treatment for this plasmacytoma before.
- You must be able to receive radiation as planned.
- Your general health and activity level must be OK (ECOG 2 or less).
- You should not have major uncontrolled infections or another active cancer.
- You must have blood counts, liver, and kidney function within required limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining a focused, high-dose radiation treatment (SBRT) with the drug lenalidomide for people with a single plasma cell tumor (solitary plasmacytoma). The goal is to see if this combination works better than radiation alone.
This trial tests a new combination of radiation therapy and a bispecific antibody (a drug that helps your immune system attack cancer cells) for people with a single bone plasmacytoma that has only a small number of abnormal cells in the bone marrow. It aims to see if this approach can control the disease better than radiation alone.
This trial tests a new combination of drugs (CM336, isatuximab, bortezomib, and lenalidomide) for people newly diagnosed with primary plasma cell leukemia, a rare and aggressive blood cancer. It aims to see if this combination can help control the disease better.
This trial tests how well a combination of daratumumab, bortezomib, and dexamethasone works in people with plasmablastic lymphoma that has returned or did not respond to prior treatment. It aims to shrink measurable tumors and improve outcomes, including for some people living with HIV.
This trial tests whether adding chemotherapy to radiation therapy after surgery can help prevent head and neck cancer from coming back. It is for people who have certain risk factors after their surgery but no signs of cancer spread.
This Phase 2 study tests whether adding intrathecal methotrexate (a cancer drug delivered into the spinal fluid) to standard chemo can lower the risk of diffuse large B-cell lymphoma (DLBCL) coming back in the brain or spinal fluid. It is for people with higher-than-usual risk of central nervous system (CNS) relapse.
Hear when a new Solitary Plasmacytoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.